Display options
Cite
Tomaro-Duchesneau C, Saha S, Malhotra M, et al. Probiotic Ferulic Acid Esterase Active Lactobacillus fermentum NCIMB 5221 APA Microcapsules for Oral Delivery: Preparation and in Vitro Characterization. Pharmaceuticals (Basel). 2012;5(2):236-48doi: 10.3390/ph5020236.
Tomaro-Duchesneau, C., Saha, S., Malhotra, M., Coussa-Charley, M., Kahouli, I., Jones, M. L., Labbé, A., & Prakash, S. (2012). Probiotic Ferulic Acid Esterase Active Lactobacillus fermentum NCIMB 5221 APA Microcapsules for Oral Delivery: Preparation and in Vitro Characterization. Pharmaceuticals (Basel, Switzerland), 5(2), 236-48. https://doi.org/10.3390/ph5020236
Tomaro-Duchesneau, Catherine, et al. "Probiotic Ferulic Acid Esterase Active Lactobacillus fermentum NCIMB 5221 APA Microcapsules for Oral Delivery: Preparation and in Vitro Characterization." Pharmaceuticals (Basel, Switzerland) vol. 5,2 (2012): 236-48. doi: https://doi.org/10.3390/ph5020236
Tomaro-Duchesneau C, Saha S, Malhotra M, Coussa-Charley M, Kahouli I, Jones ML, Labbé A, Prakash S. Probiotic Ferulic Acid Esterase Active Lactobacillus fermentum NCIMB 5221 APA Microcapsules for Oral Delivery: Preparation and in Vitro Characterization. Pharmaceuticals (Basel). 2012 Feb 16;5(2):236-48. doi: 10.3390/ph5020236. PMID: 24288090; PMCID: PMC3763630.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2012 Feb 16;5(2):236-48. doi: 10.3390/ph5020236.

Probiotic Ferulic Acid Esterase Active Lactobacillus fermentum NCIMB 5221 APA Microcapsules for Oral Delivery: Preparation and in Vitro Characterization.

Pharmaceuticals (Basel, Switzerland)

Catherine Tomaro-Duchesneau, Shyamali Saha, Meenakshi Malhotra, Michael Coussa-Charley, Imen Kahouli, Mitchell L Jones, Alain Labbé, Satya Prakash

Affiliations

  1. Biomedical Technology and Cell Therapy Research Laboratory, Departments of Biomedical Engineering, Physiology, and Artificial Cells and Organs Research Center, Faculty of Medicine, McGill University, 3775 University Street, Montreal, Quebec, H3A 2B4, Canada. [email protected].

PMID: 24288090 PMCID: PMC3763630 DOI: 10.3390/ph5020236

Abstract

Probiotics possess potential therapeutic and preventative effects for various diseases and metabolic disorders. One important limitation for the oral delivery of probiotics is the harsh conditions of the upper gastrointestinal tract (GIT) which challenge bacterial viability and activity. One proposed method to surpass this obstacle is the use of microencapsulation to improve the delivery of bacterial cells to the lower GIT. The aim of this study is to use alginate-poly-L-lysine-alginate (APA) microcapsules to encapsulate Lactobacillus fermentum NCIMB 5221 and characterize its enzymatic activity and viability through a simulated GIT. This specific strain, in previous research, was characterized for its inherent ferulic acid esterase (FAE) activity which could prove beneficial in the development of a therapeutic for the treatment and prevention of cancers and metabolic disorders. Our findings demonstrate that the APA microcapsule does not slow the mass transfer of substrate into and that of the FA product out of the microcapsule, while also not impairing bacterial cell viability. The use of simulated gastrointestinal conditions led to a significant 2.5 log difference in viability between the free (1.10 × 104 ± 1.00 × 103 cfu/mL) and the microencapsulated (5.50 × 106 ± 1.00 × 105 cfu/mL) L. fermentum NCIMB 5221 following exposure. The work presented here suggests that APA microencapsulation can be used as an effective oral delivery method for L. fermentum NCIMB 5221, a FAE-active probiotic strain.

References

  1. J Agric Food Chem. 2003 Aug 27;51(18):5534-9 - PubMed
  2. Phytother Res. 2004 Apr;18(4):310-4 - PubMed
  3. Anal Biochem. 2002 Oct 1;309(1):96-101 - PubMed
  4. J Clin Gastroenterol. 2010 Apr;44(4):237-8 - PubMed
  5. Int J Biochem Cell Biol. 2002 May;34(5):439-58 - PubMed
  6. Eur J Drug Metab Pharmacokinet. 2008 Apr-Jun;33(2):101-6 - PubMed
  7. Diabetes Res Clin Pract. 2008 Jan;79(1):11-7 - PubMed
  8. Carcinogenesis. 1983 Dec;4(12):1651-3 - PubMed
  9. Eur J Clin Invest. 2006 Aug;36(8):588-96 - PubMed
  10. Arch Pharm Res. 2005 Oct;28(10):1183-9 - PubMed
  11. J Dairy Sci. 1999 Dec;82(12):2530-5 - PubMed
  12. Acta Diabetol. 2003 Sep;40(3):118-22 - PubMed
  13. Appl Environ Microbiol. 2008 Feb;74(4):1284-8 - PubMed
  14. Br J Nutr. 2010 Jun;103(12):1792-9 - PubMed
  15. FEBS Lett. 1999 Sep 17;458(2):224-30 - PubMed
  16. Appl Environ Microbiol. 2009 Sep;75(18):6013-6 - PubMed
  17. Free Radic Biol Med. 1996;20(7):933-56 - PubMed
  18. Mol Biotechnol. 2001 Mar;17(3):249-60 - PubMed
  19. Biotechnol Appl Biochem. 2008 May;50(Pt 1):1-9 - PubMed
  20. Biologics. 2011;5:71-86 - PubMed
  21. Breast Cancer Res. 2004;6(2):R63-74 - PubMed
  22. J Clin Biochem Nutr. 2007 Mar;40(2):92-100 - PubMed
  23. Cell. 2005 Feb 25;120(4):497-512 - PubMed
  24. J Agric Food Chem. 2008 Sep 10;56(17):7838-44 - PubMed
  25. Appl Microbiol Biotechnol. 2008 Nov;81(2):225-33 - PubMed
  26. J Med Food. 2009 Apr;12(2):310-9 - PubMed
  27. Curr Opin Biotechnol. 2010 Apr;21(2):175-81 - PubMed
  28. Carcinogenesis. 1993 Jul;14(7):1321-5 - PubMed
  29. Appl Environ Microbiol. 2004 Sep;70(9):5315-22 - PubMed
  30. J Nutr. 2010 Mar;140(3):698S-712S - PubMed
  31. J Biomed Biotechnol. 2007;2007(7):13684 - PubMed
  32. Anticancer Res. 1999 Sep-Oct;19(5A):3757-61 - PubMed
  33. J Biomed Biotechnol. 2011;2011:981214 - PubMed

Publication Types